News Another LAG-3 setback as Regeneron drug fails phase 3 trial Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
News NICE backs stomach cancer, PAH drugs for NHS use AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
News FDA hands BeOne, Taiho approvals for blood cancers BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.
News AZ cues up broader use of Imfinzi in bladder cancer The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.
News BMS signs $15.2bn R&D alliance with China's Hengrui Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.
News Partner's Bizengri is first drug for rare, aggressive cancer Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
